Alcami to establish active pharmaceutical ingredient Center of Excellence

Freeman Staff

Sept. 7, 2017

Alcami Corp., a provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, announced Wednesday the formation of a Center of Excellence at its active pharmaceutical ingredient development and manufacturing facility in Germantown.

“The establishment of a Center of Excellence for API development, scale-up and commercialization in Germantown, coupled with our extensive regulatory expertise greatly strengthens the foundation of our business and allows innovators to execute all parts of API development and manufacturing in one U.S.-based location to support their launch,” said Dr. Stephan Kutzer, CEO, president and chairman of Alcami Corp., in a news release. “We are excited to expand our capabilities and fuel the growth and success of Alcami while simultaneously upholding the commitment to our customers to deliver seamless, efficient end-to-end small molecule services.”

Demand for Alcami’s end-to-end offering contributed to the company’s strategic decision to expand, the release said. End-to-end projects have grown to become a significant part of the company's project portfolio since the program’s inception in March 2016, representing 10 percent of its total business. Approximately 62 percent of those projects originate from the Germantown site.